Melief et al. reported high ORR and DCR of 43% and 86%, respectively, and found significantly improved OS in a group of 77 cervical cancer patients with strong (higher than the median) immunological vaccine responses compared to those with low (lower than the median) immunological vaccine responses (16.8 months vs. 11.2 months; p = 0.012) when treated with an HPV E6 and E7 peptide-based vaccine ± pegylated INFα in addition to chemotherapy [43]. Here, IFNA17 is linked to cervical cancer.